Floatz logo

FLORTAUCIPIR

Frontotemporal Dementia

Mayo ClinicSmall moleculePhase 4 / ApprovedActive
BBB
73/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
63/ 100
Competitive Position
89/ 100

Competitive context

24 Active assets in the Frontotemporal Dementia cohort.

Asset / SponsorPhaseRating
FLUDEOXYGLUCOSE
University of Michigan
Phase 4BB
CITALOPRAM
Sunnybrook Health Sciences Centre
Phase 4BB
PITTSBURGH COMPOUND B UNLABELLED
Mayo Clinic
Phase 4BB
LEMBOREXANT
Nova Scotia Health Authority
Phase 4BB
IZAFLORTAUCIPIR
University of Pennsylvania
Phase 3BB

View all 41 →

Same molecule, other indications

FLORTAUCIPIR is also rated in:

Alzheimer diseaseDormant
BBB
Indicative ·
73 / 100
View asset →
primary progressive aphasiaDormant
BBB
Indicative ·
72 / 100
View asset →
progressive non-fluent aphasiaDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →